891 related articles for article (PubMed ID: 16117975)
1. Therapeutic options for pneumococcal pneumonia in Turkey.
Oncu S; Erdem H; Pahsa A
Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
[TBL] [Abstract][Full Text] [Related]
2. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
4. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
6. E test for studying in vitro activity of seven antimicrobial agents against penicillin-susceptible and penicillin-resistant pneumococci.
Li J; Zhang Y; Chen Y; Hao F; Chen Y
Chin Med J (Engl); 2000 Jul; 113(7):628-31. PubMed ID: 11776034
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
Seral C; Suárez L; Rubio-Calvo C; Gómez-Lus R; Gimeno M; Coronel P; Durán E; Becerril R; Oca M; Castillo FJ
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
Feldman C
J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
[TBL] [Abstract][Full Text] [Related]
10. [Carrier rate of Streptococcus pneumoniae and susceptibility thereof to antimicrobial drugs among children in China: a surveillance study in Beijing, Shanghai, and Guangzhou 2000-2002].
Yao KH; Lu Q; Deng L; Yu SJ; Zhang H; Deng QL; Shen XZ; Yang YH
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(28):1957-61. PubMed ID: 16313770
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
[TBL] [Abstract][Full Text] [Related]
12. Streptococcus pneumoniae: does antimicrobial resistance matter?
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
[TBL] [Abstract][Full Text] [Related]
13. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies.
Gums JG; Boatwright DW; Camblin M; Halstead DC; Jones ME; Sanderson R
Ann Pharmacother; 2008 Jan; 42(1):71-9. PubMed ID: 18094350
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
Pottumarthy S; Fritsche TR; Sader HS; Stilwell MG; Jones RN
Int J Antimicrob Agents; 2005 Apr; 25(4):282-9. PubMed ID: 15784306
[TBL] [Abstract][Full Text] [Related]
15. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors.
Aspa J; Rajas O; Rodríguez de Castro F; Blanquer J; Zalacain R; Fenoll A; de Celis R; Vargas A; Rodríguez Salvanés F; España PP; Rello J; Torres A;
Clin Infect Dis; 2004 Mar; 38(6):787-98. PubMed ID: 14999620
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and clinical outcomes of penicillin resistant S. pneumoniae community-acquired pneumonia in Khon Kaen, Thailand.
Reechaipichitkul W; Assawasanti K; Chaimanee P
Southeast Asian J Trop Med Public Health; 2006 Mar; 37(2):320-6. PubMed ID: 17124993
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
[TBL] [Abstract][Full Text] [Related]
18. Resistance among Streptococcus pneumoniae: Implications for drug selection.
Appelbaum PC
Clin Infect Dis; 2002 Jun; 34(12):1613-20. PubMed ID: 12032897
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility patterns of Streptococcus pneumoniae in Mexico.
Quiñones-Falconi F; Calva JJ; López-Vidal Y; Galicia-Velazco M; Jiménez-Martinez ME; Larios-Mondragón L
Diagn Microbiol Infect Dis; 2004 May; 49(1):53-8. PubMed ID: 15135501
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium.
Lismond A; Carbonnelle S; Verhaegen J; Schatt P; De Bel A; Jordens P; Jacobs F; Dediste A; Verschuren F; Huang TD; Tulkens PM; Glupczynski Y; Van Bambeke F
Int J Antimicrob Agents; 2012 Mar; 39(3):208-16. PubMed ID: 22245497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
